A drug shortage in India has forced doctors to ration two critical chemotherapy medications, cisplatin and carboplatin, following supply disruptions linked to the Iran conflict. Samaan Lateef reports from Mumbai for The Lancet that treatment for cancer patients is being interrupted as a result.
The shortage stems from the ongoing Iran conflict, which has disrupted supply chains for these platinum-based drugs. Cisplatin and carboplatin are cornerstone treatments for various cancers, including lung, ovarian, and testicular cancers, making their scarcity a serious public health concern.
According to the report, clinicians are now forced to prioritize which patients receive full doses, while others face delayed or reduced treatment regimens. The exact scale of the shortage remains unclear, but the impact on patient outcomes is expected to be significant.
The disruptions highlight the vulnerability of global pharmaceutical supply chains to geopolitical conflicts. India, a major producer of generic drugs, may need to seek alternative suppliers or boost domestic production to mitigate future risks.
Experts warn that without swift intervention, the mortality rate among affected cancer patients could rise, though no specific data on excess deaths has been provided.